23andMe cuts 40% of its workforce and discontinues therapeutics division
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe on Monday.
23andMe announces layoffs, will cut 40% of workforce
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed drawn-out negotiations with Wojcicki, who has been trying to take the company private. The seven resigning directors said they had yet ...
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
The restructuring arrives during a period of turmoil at the company that has included a high-profile data breach and several rounds of previous layoffs.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
What 23andMe business troubles could mean for millions of users' genetic data
The financial struggles of genetic testing and ancestry company 23andMe are raising questions about the security of customers ...
NBC Los Angeles2d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
Hosted on MSN2d
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly ... The company announced two weeks ago that it had ...
23andMe appoints three former CFOs as new directors—after the previous board all resigned
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...
Rolling Out1d
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...
Yahoo Finance16d
23andMe Appoints Three New Independent Directors to Board
Ms. Wojcicki added, “I am excited to welcome these three experienced directors to the 23andMe Board, and looking forward to working with them.” Mr. Jensen has substantial financial and ...
Benzinga.com2d
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
BBC on MSN2d
DNA-testing site 23andMe to lay off 40% of its workers
In another blow to the company, seven of 23andMe’s eight-strong board resigned in September. The firm's independent ...